CG Oncology bladder immunotherapy cretostimogene cut recurrence risk by 68% in phase 3 study
CG Oncology reported Monday that its bladder cancer immunotherapy cretostimogene reduced the risk of tumor recurrence by 68% compared with current medical practice, results from a randomized Phase 3 trial that may change how physicians treat some patients with the disease. Cretostimogene, often called “creto,” is built from a common-cold virus engineered to target cells that express a mutation found in bladder tumors. Doctors infuse it through a catheter directly into the bladder, where it enters the mutated cancer cells, replicates rapidly, and ruptures those cells.
The study enrolled 367 patients with intermediate-risk bladder cancer, a localized form typically removed with minimally invasive surgery and then watched every three months. Recurrence can mean repeat operations; over time, bladder function can decline and the cancer can keep growing. The trial compared cretostimogene with that standard of care rather than with a new rival drug. The source’s remaining clinical details sit behind a STAT+ paywall, so further endpoints, safety data, and subgroup results were not available in the published excerpt.
Continue in the app — vote & join in ➔